neurocare Group Announces FDA Clearance For Apollo TMS Therapy Devices As Treatment For Adolescents With Major Depression

neurocare group AG (“neurocare” or the “Company”) announced that it has received FDA clearance for the treatment of Major Depressive Disorder (MDD) in adolescents using its Apollo TMS Therapy devices and Transcranial Magnetic Stimulation (TMS).

Currently, only two oral antidepressants are FDA-approved for use in this age group, and both carry a “black box” warning—the strongest warning the FDA issues for medications—due to an increased risk of suicidal thoughts and actions, the announcement stated. These medications have an effectiveness rate of only about 35% in achieving remission, according to the announcement.

TMS offers a safe, non-invasive . . .